NurExone Advances Exosome-Based ExoPTEN Toward Clinical Development for Spinal Cord and Optic Nerve Regeneration
核心洞察
NurExone Biologic's exosome-based candidate ExoPTEN has produced striking preclinical results, with 100% of animals in a high-dose group regaining walking ability after spinal cord injury (搜索).
The company has secured Orphan Drug designations from both the EMA and FDA and completed a Pre-IND meeting with the FDA ahead of a planned Phase 1/2a trial.
ExoPTEN also shows dose-dependent regenerative potential in an optic nerve crush model, with higher doses achieving retinal electrical activity comparable to uninjured eyes.
NurExone Biologic Inc. (搜索) is preparing to advance its lead therapeutic candidate, ExoPTEN, from preclinical development into human clinical testing. The exosome-based therapy, designed to stimulate regenerative processes in the damaged nervous system, has demonstrated what the company describes as unprecedented preclinical results in models of spinal cord injury (搜索) and optic nerve damage (搜索). The company is now positioning itself for the transition from animal studies to clinical trials, with institutional investor engagement and manufacturing partnerships forming key components of its path forward.
Preclinical Evidence in Acute Spinal Cord Injury
The most advanced program targets acute spinal cord injury (搜索). Across multiple preclinical studies, ExoPTEN produced marked functional improvements. In one animal model, 75 percent of treated animals showed signs of functional recovery. In a later investigation, 100 percent of animals in the high-dose group regained their ability to walk. The results extended beyond motor function, with studies also indicating improved blood flow, preservation of nerve cells, and structural repair processes within the injured spinal cord. Notably, ExoPTEN demonstrated therapeutic potential even when administered several days after the acute injury phase.
Following transection or damage to the spinal cord, the test animals learned to walk again — reaching 100 percent in the final trial series within the high-dose group — with not only nerve fibers reconnecting but also the myelin sheath regenerating.
Regulatory Milestones and Path to the Clinic
NurExone has achieved several important regulatory milestones. ExoPTEN received Orphan Drug designation from the European Medicines Agency (EMA) for the treatment of acute spinal cord injuries, and it has since secured a corresponding designation from the US Food and Drug Administration (FDA). The company has also completed a Pre-IND meeting with the FDA and advanced preparations for a Phase 1/2a clinical study, bringing the program closer to the decisive step from animal models to human application.
Optic Nerve Regeneration Program
NurExone is pursuing a second, longer-term indication: regeneration of the damaged optic nerve. The company is evaluating ExoPTEN in an optic nerve crush model, in which the optic nerve of animals is deliberately damaged. Results to date suggest that ExoPTEN may not only protect retinal ganglion cells but also promote regenerative processes within the optic nerve. Further investigations observed improvements in retinal activity and structural changes. A particularly notable finding was a dose-dependent effect, in which the higher ExoPTEN dose achieved values in certain measurements of retinal electrical activity that were comparable to uninjured eyes.
Proprietary Exosome Platform and Anti-Inflammatory Activity
The therapeutic approach is built on exosomes produced using NurExone's patented method. Independent assessments identified 11 proteins with potential therapeutic benefit in the NurExone exosomes — none of which are found in commercially available exosomes. When combined with a specific siRNA (a PTEN (搜索) inhibitor), these exosomes form a drug candidate intended to deliver regenerative cargo directly to sites of neuronal damage.
In laboratory analyses, exosomes produced by NurExone's proprietary method reduced levels of IL-6, a key inflammatory signaling molecule, by more than 86 percent compared to untreated inflamed cells, even at the lowest tested concentration. For TNF-alpha (搜索), another central inflammatory signal, the NurExone exosomes showed a concentration-dependent reduction in inflammatory signaling, reaching reductions of over 60 percent at the highest tested concentration compared to the untreated inflamed control. In contrast, commercially available exosome products showed no or only minimal reduction of both inflammatory signals at the analyzed concentrations.
Manufacturing and Commercialization
To support its longer-term development, NurExone announced a binding memorandum of understanding (MOU) with Made Scientific (搜索) for US-based GMP manufacturing and a commercial supply partnership. The company has also signaled preparations for "potential clinical development" and the "manufacturing and commercial capabilities that may be required for the Company's longer-term development," reflecting a shift in focus from research toward production and eventual commercialization.
Investor Engagement
Co-Founder, VP Strategic Development, and Chairman Yoram Drucker is scheduled to present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference, where he will also "participate in scheduled one-on-one meetings with investors." The event is described by Moody Capital as an "industry flagship conference" serving small- and mid-cap companies across biotech, medtech, pharma, and healthcare, with an audience of qualified investors and experienced capital market participants. The company has also indicated plans for a potential listing on a major US exchange such as the Nasdaq.
The decisive next milestone for NurExone is expected to be the first clinical study in humans. Should the regenerative effects observed in animal models be confirmed in patients, the company's exosome-based approach could hold significant implications for the treatment of nerve damage that is currently only very limitedly treatable.